A. Sinclair Dunlop

CIK 1721108 · last filed 2026-05-14

A. Sinclair Dunlop is a corporate insider who has filed 46 SEC Form 4 insider transactions across 1 company since 2017. The most recent filing, for APLS, was dated May 14, 2026. Across all open-market trades the lifetime net is −$28.1M, making them a net seller over the disclosed history.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

1

Total Filings

46

Lifetime Open-Market Net

-$28.11M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Apellis Pharmaceuticals, Inc. (APLS) Delisted Director 0 $41.03 $0 -$28.11M 46 2026-05-14

Recent Filings

46 filings
Form 4 transactions across all companies, newest first.
Filed Symbol Action Net Shares Net $ Link
2026-05-14 Apellis Pharmaceuticals, Inc. (APLS) Delisted Mixed −181,878 $0 EDGAR
2026-01-05 Apellis Pharmaceuticals, Inc. (APLS) Delisted Grant (A) +7,961 $0 EDGAR
2025-10-15 Apellis Pharmaceuticals, Inc. (APLS) Delisted Mixed −39,716 -$737.5K EDGAR
2025-10-02 Apellis Pharmaceuticals, Inc. (APLS) Delisted Mixed −34,929 -$702.1K EDGAR
2025-09-19 Apellis Pharmaceuticals, Inc. (APLS) Delisted Mixed −34,929 -$713.6K EDGAR
2025-01-03 Apellis Pharmaceuticals, Inc. (APLS) Delisted Grant (A) +6,267 $0 EDGAR
2024-09-24 Apellis Pharmaceuticals, Inc. (APLS) Delisted Exer (M) +4,600 $60.7K EDGAR
2024-09-17 Apellis Pharmaceuticals, Inc. (APLS) Delisted Sell (S) −37,000 -$1.34M EDGAR
2024-07-01 Apellis Pharmaceuticals, Inc. (APLS) Delisted Exer (M) +900 $11.9K EDGAR
2024-06-21 Apellis Pharmaceuticals, Inc. (APLS) Delisted Sell (S) −37,000 -$1.45M EDGAR
Showing 110 of 46
Page 1 of 5
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.